Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo

Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo

Dasatinib is a targeted cancer therapy, while programmed death ligand 1 (PD-L1) inhibitors are a form of immune checkpoint therapy used to treat various types of cancers. Several studies showed the potential efficacy of these drugs in the management of triple-negative breast cancer- an aggressive su...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Maha, Al-Asmakh (author)
مؤلفون آخرون: Bawadi, Hiba (author), Hamdan, Munia (author), Gupta, Ishita (author), Kheraldine, Hadeel (author), Jabeen, Ayesha (author), Rizeq, Balsam (author), Al Moustafa, Ala-Eddin (author)
التنسيق: article
منشور في: 2020
الموضوعات:
Dasatinib
PD-L/PD-L1
Embryo
Angiogenesis
Chorioallantoic membrane
Toxicity
الوصول للمادة أونلاين:http://dx.doi.org/10.1016/j.biopha.2020.111134
https://www.sciencedirect.com/science/article/pii/S0753332220313275
http://hdl.handle.net/10576/17228
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

الانترنت

http://dx.doi.org/10.1016/j.biopha.2020.111134
https://www.sciencedirect.com/science/article/pii/S0753332220313275
http://hdl.handle.net/10576/17228

مواد مشابهة